Back to today’s briefing

Story perspectives

ICER: Rising Drug Prices Cost $1.5 Billion Annually

10/24/2025

30 4

Summary

Story summary

The Institute for Clinical and Economic Review (ICER) reports the median net launch price rose 51% from 2022 to 2024.
The list price rose 24% in the same period.
Aligning prices with ICER benchmarks could have saved $1.3–$1.5 billion in the first year after approval.
Critics say ICER's methodology overlooks the full value of medicines.
In early 2025, about half of prescriptions were rejected by insurance.

1 of 1

Story summary

The Institute for Clinical and Economic Review (ICER) reports the median net launch price rose 51% from 2022 to 2024.
The list price rose 24% in the same period.
Aligning prices with ICER benchmarks could have saved $1.3–$1.5 billion in the first year after approval.
Critics say ICER's methodology overlooks the full value of medicines.
In early 2025, about half of prescriptions were rejected by insurance.